ReviewJournal of medical ultrasonics (2001)2026
The clinical utility and diagnostic performance of transabdominal contrast-enhanced ultrasonography using Sonazoid for pancreatic diseases: a narrative review.
Review in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to evaluate the clinical utility of contrast-enhanced ultrasonography (CEUS) in the differential diagnosis and management of solid and cystic pancreatic lesions. We reviewed the characteristic enhancement patterns of various solid and cystic pancreatic diseases, including pancreatic ductal adenocarcinoma (PDAC), mass-forming pancreatitis (MFP), focal autoimmune pancreatitis (AIP), pancreatic neuroendocrine neoplasms (PNENs), solid pseudopapillary neoplasms (SPNs), metastatic tumors, intraductal papillary mucinous neoplasms (IPMNs), serous cystic neoplasms (SCNs), and mucinous cystic neoplasms (MCNs). We also analyzed the role of quantitative perfusion analysis and summarized diagnostic performance based on multicenter studies and meta-analyses. In PDAC, the "irregular rolling sign" and early washout under a hypovascular pattern are critical diagnostic markers reflecting histological desmoplasia. Conversely, MFP typically shows diffuse isovascularity. CEUS facilitates the differentiation of malignant mural nodules from mucus plugs in IPMN with high accuracy. Quantitative perfusion analysis (QPA) using time-intensity curves (TIC) provides objective metrics like peak intensity (PI) and area under the curve (AUC), enhancing diagnostic objectivity. Large-scale studies, such as the Pancreatic Multicenter Ultrasound Study (PAMUS), and several meta-analyses have demonstrated that CEUS achieves a pooled sensitivity of 86-90% and specificity of 75-88% for pancreatic cancer, outperforming or equaling conventional CT and B-mode ultrasound. CEUS is a minimally invasive, rapid, and highly accurate modality that provides essential hemodynamic information. It should be considered a valuable complementary imaging modality for the initial evaluation and stratification of pancreatic neoplastic lesions, particularly when detailed hemodynamic assessment is required alongside conventional screening.
Indexed as
Identifiers
42667502What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.